SPOP and prostate carcinoma: Our study reveals that SPOP mutations augment Caprin1-mediated SG assembly and render prostate cancer cells resistance to docetaxel, suggesting that targeting the SG assembly pathway represents a viable strategy to restore docetaxel sensitivity in prostate cancer cells.